Evaluation of p53 mutation as a predictive biomarker for outcome to chemotherapy in ovarian cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include ...
Retrospective study of unresectable stage III or stage IV melanoma refractory to immune checkpoint and BRAF/MEK inhibitors, treated with triplet vs doublet therapy: A single institution experience.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results